Overview of direct oral anticoagulant therapy reversal

American Journal of Health-System Pharmacy

Volumn 73, Issue 10, 2016, Pages S5-S13

  Gulseth, Michael P ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; FRESH FROZEN PLASMA; IDARUCIZUMAB; PROTHROMBIN COMPLEX; RIVAROXABAN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BLOOD TRANSFUSION; CLINICAL LABORATORY; DISEASE SEVERITY; DRUG MECHANISM; EMERGENCY CARE; HUMAN; INVASIVE PROCEDURE; MEDICAL EDUCATION; PHARMACIST; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; COMPLICATION; HEMORRHAGE; ORAL DRUG ADMINISTRATION; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; HEMORRHAGE; HUMANS; THROMBOEMBOLISM;

EID: 84968909109     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp150966     Document Type: Review

References (50)

1. Boehringer Ingelheim Pharmaceuticals. Pradaxa (dabigatran etexilate mesylate) prescribing information. http:// docs.boehringer-ingelheim.com/ Prescribing%20Information/PIs/ Pradaxa/Pradaxa.pdf (accessed 2016 Jan 7).
2. Bristol-Myers Squibb. Eliquis (apixaban) prescribing information. http://packageinserts.bms.com/pi/ pi-eliquis.pdf (accessed 2015 Jul 30).
3. Daiichi Sankyo. Savaysa (edoxaban) prescribing information. http:// dsi.com/prescribing-informationportlet/getPIContent?productName =Savaysa&inline=true (accessed 2015 Jul 30).
4. Janssen Pharmaceuticals. Xarelto (rivaroxaban) prescribing information. www.xareltohcp.com/ shared/product/xarelto/prescribinginformation.pdf (accessed 2015 Jul 30).
5. Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol. 2015; 35:1056-65.
6. Blech S, Ebner T, Ludwig-Schwellinger E et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008; 36:386-99.
7. Stangier J, Rathgen K, Stähle H et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64:292-303.
8. Kubitza D, Becka M, Wensing G et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005; 61:873-80.
9. Weinz C, Schwarz T, Kubitza D et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2009; 37:1056-64.
10. Frost C, Nepal S, Wang J et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013; 76:776-86.
11. Raghavan N, Frost CE, Yu Z et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009; 37:74-81.
12. Bathala MS, Masumoto H, Oguma T et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012; 40:2250-5.
13. Ogata K, Mendell-Harary J, Tachibana M et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010; 50:743-53.
14. Dager WE. Developing a management plan for oral anticoagulant reversal. Am J Health-Syst Pharm. 2013; 70(suppl 1):S21-31.
15. Peacock WF, Gearhart MM, Mills RM. Emergency management of bleeding associated with old and new oral anticoagulants. Clin Cardiol. 2012; 35:730-7.
16. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139-51.
17. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369:2093-104.
18. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981-92.
19. Hohnloser SH, Oldgren J, Yang S et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012; 125:669-76.
20. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883-91.
21. Dougherty J, Oyen LJ, Dager WE. Anticoagulation reversal. In: Dager WE, Gulseth MP, Nutescu EA, eds. Anticoagulation therapy: a point-ofcare guide. Bethesda, MD: American Society of Health-System Pharmacists; 2011:123-54.
22. Brem E, Koyfman A, Foran M. Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians. J Emerg Med. 2013; 45:143-9.
23. Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124:1573-9.
24. Dzik WH. Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisal. J Thromb Haemost. 2015; 13(suppl 1):S187-94.
25. Nutescu EA, Dager WE, Kalus JS et al. Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations. Am J Health-Syst Pharm. 2013; 70:1914-29.
26. Dager W, Hellwig T. Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants. Am J Health-Syst Pharm. 2016; 73(suppl 2):S14-26
27. Prasad Kerlin M, Tokar JL. Acute gastrointestinal bleeding. Ann Intern Med. 2013; 159:ITC2-1.
28. Dries DJ, Morton CT. Coagulation: part 2. Air Med J. 2014; 33:246-9.
29. Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health-Syst Pharm. 2012; 69:1473-84.
30. Pollack CV Jr. Managing bleeding in anticoagulated patients in the emergency care setting. J Emerg Med. 2013; 45:467-77.
31. Willis CM, Hall AB. Use of four-factor prothrombin complex concentrate in the emergency department: a review. J Emerg Nurs. 2015; 41:9-12.
32. Wood P. New oral anticoagulants: an emergency department overview. Emerg Med Australas. 2013; 25:503-14.
33. Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17:1467-507.
34. Sarma A, Giugliano RP. Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation. Hosp Pract. 2015; 43:258-67.
35. Sartori MT, Prandoni P. How to effectively manage the event of bleeding complications when using anticoagulants. Expert Rev Hematol. 2016; 9:37-50.
36. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J. 2013; 34:489-98b.
37. Henry DA, Carless PA, Moxey AJ et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011; 3:CD001886.
38. Shakur H, Roberts I, Bautista R et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010; 376:23-32.
39. Van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103:1116-27.
40. Smythe MA, Trujillo T, Fanikos J. Reversal agents for use with direct and indirect anticoagulants. Am J Health-Syst Pharm. 2016; 73(suppl 2):S27-48.
41. Kuramatsu JB, Gerner ST, Schellinger PD et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015; 313:824-36.
42. Hsia CC, Zurawska JH, Tong MZ et al. Recombinant activated factor VII in the treatment of non-haemophilia patients: physician under-reporting of thromboembolic adverse events. Transfus Med. 2009; 19:43-9.
43. Boehringer Ingelheim. Praxbind prescribing information. www. accessdata.fda.gov/drugsatfda-docs/ label/2015/761025lbl.pdf (accessed 015 Oct 22).
44. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost. 2015; 113:931-42.
45. Lu G, DeGuzman FR, Hollenbach SJ et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013; 19:446-51.
46. Pollack CV Jr, Reilly PA, Eikelboom J et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015; 373:511-20.
47. Glund S, Moschetti V, Norris S et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015; 113:943-51.
48. Schiele F, van Ryn J, Canada K et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013; 121:3554-62.
49. Siegal DM, Curnutte JT, Connolly SJ et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015; 373:2413-24.
50. Ansell JE, Bakhru SH, Laulicht BE et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014; 371:2141-2.